Epidaza (Chidamide) is the first marketed innovative drug developed by a Chinese pharmaceutical company. As an oral HDAC inhibitor, Epidaza targets recurrent peripheral T cell lymphoma. Meanwhile, it can also treat other hematological cancer, solid tumor and even HIV combined with other drugs. Multiple clinical trials are conducted in the U.S., Japan, China and Taiwan.